VIRTUSO/ENTRUST/MAXIMO/INTRINSIC/MARQUIS/IMPLANTABLE CARDIVERTER DEFIBRILLATORS
Medtronic Cardiac Rhythm Disease Management · Decision date Oct 9, 1998
What did the FDA approve?
The October 9, 1998 FDA statement records approval for the Medtronic Model 7271 GEM DR Dual Chamber Implantable Cardioverter Defibrillator System with Model 9960 application software, Model 6940 CapSureFix Lead, and Model 9466 Patient Magnet. The stated indication covers patients at risk of sudden death due to ventricular arrhythmias who have survived at least one cardiac arrest with loss of consciousness from ventricular tachyarrhythmia, or who have recurrent, poorly tolerated, sustained ventricular tachycardia.
The same dated statement notes that the clinical outcome for hemodynamically stable VT patients is not fully known and that safety and effectiveness studies have not been conducted for that group. The document does not describe trial data, labeling changes, or any relationship to a prior PMA. No supplement type or reason is supplied, so the specific regulatory action beyond the original approval cannot be characterized from the available fields.
FDA approval order statement
Approval for the Medtronic(R) Model 7271 GEM(TM) DR Dual Chamber Implantable Cardioverter Defibrillator System with Mdoel 9960 (GEM(TM) DR) Application Software, Medtronic(R) Model 6940 CapSureFix(R) Lead and Model 9466 Patient Magnet. This system is indicated for use in patients who are at risk of sudden death due to ventricular arrhythmias and have experienced one of the following situations: survival of at least one episode of cardiac arrest (manifested by loss of consciousness) due to ventricular tachyarrhythmia or recurrent, poorly tolerated, sustained ventricular tachycardia. (Note: the clinical outcome for hemodynamically stable VT patients is not fully known. Safety and effectiveness studies have not been conducted.)
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 9, 1998
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980016
- Regulatory pathway
- Premarket approval application
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Oct 9, 1998
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Product code
- LWS
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P980016 received
Application receipt date recorded by FDA.
P980016 · FDA decision
APPR
P980016/S965 · Related supplement
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD
P980016/S966 · Related supplement
Cobalt MRI ICD (DDPB3Dl, DDPB3D4, DVPB3Dl, DVPB3D4); Cobalt XT MRI ICD (DDPA2Dl, DDPA2D4, DVPA2Dl, DVPA2D4); Crome MRI I
P980016/S967 · Related supplement
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD
P980016/S964 · Related supplement
Cobalt MRI ICD (DDPB3D1, DDPB3D4, DVPB3D1, DVPB3D4); Cobalt XT MRI ICD (DDPA2D1, DDPA2D4, DVPA2D1, DVPA2D4); Crome MRI I
Timeline entries are records held by MedtechLedger for P980016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S965 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cardiac Rhythm Disease Management
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P980016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




